Real-World Treatment Patterns, Healthcare Resource Use and Disease Burden in Patients with Multiple Myeloma in Europe

References

• Rajkumar SV . Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol.91(7), 719–734 (2016).
   PubMed Web of Science ®Google Scholar
• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Cancer incidence in Europe 2020 factsheet. Published March 2021. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf
   Google Scholar
• Moreau P , SanMiguel J, SonneveldPet al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.28(Suppl. 4), iv52–iv61 (2017).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA , MoreauP, TerposEet al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.32(3), 309–322 (2021).
   PubMed Web of Science ®Google Scholar
• Szalat R , MunshiNC. Novel Agents in Multiple Myeloma. Cancer J25(1), 45–53 (2019).
   PubMed Web of Science ®Google Scholar
• Maiese EM , EvansKA, ChuB-C, IrwinDE. Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States. Am Health Drug Benefits11(1), 39–46 (2018).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV . Updated Diagnostic Criteria and Staging System for Multiple Myeloma. American Society of Clinical Oncology Educational Book36, e418–e423doi:10.1200/edbk_159009 (2016).
   Google Scholar
• Gandhi UH , CornellRF, LakshmanAet al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia33(9), 2266–2275 (2019).
   PubMed Web of Science ®Google Scholar
• Mateos M-V , WeiselK, StefanoVDet al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy. J. Clin. Oncol.39(Suppl. 15), 8041–8041 (2021).
   Web of Science ®Google Scholar
• Anderson P , BenfordM, HarrisN, KaravaliM, PiercyJ. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr. Med. Res. Opin.24(11), 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Babineaux SM , CurtisB, HolbrookT, MilliganG, PiercyJ. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open6(8), e010352 (2016).
   PubMed Web of Science ®Google Scholar
• Higgins V , PiercyJ, RoughleyAet al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes9, 371–380 (2016).
   PubMed Web of Science ®Google Scholar
• Code of Conduct. https://www.ephmra.org/code-conduct-aer (17 August 2022).
   Google Scholar
• Summary of the HIPAA Privacy Rule. http://www.hhs.gov/sites/default/files/privacysummary.pdf (17 August 2022).
   Google Scholar
• Brooks R . EuroQol: the current state of play. Health Policy37(1), 53–72 (1996).
   PubMed Web of Science ®Google Scholar
• Pickard AS , NearyMP, CellaD. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes5, 70 (2007).
   PubMed Web of Science ®Google Scholar
• EORTC QLQ-C30 Scoring Manual. https://www.eortc.be/qol/files/SCManualQLQ-C30.pdf (29 October 2018).
   Google Scholar
• Velikova G , CoensC, EfficaceFet al. Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice. European Journal of Cancer Supplements10(1), 141–149 (2012).
   Google Scholar
• Kvam AK , FayersP, WisloffF. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur. J. Haematol.84(4), 345–353 (2010).
   PubMed Web of Science ®Google Scholar
• Cocks K , CohenD, WisloffFet al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur. J. Cancer43(11), 1670–1678 (2007).
   PubMed Web of Science ®Google Scholar
• Stead ML , BrownJM, VelikovaGet al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br. J. Haematol.104(3), 605–611 (1999).
   PubMed Web of Science ®Google Scholar
• Sully K , TriggA, BonnerNet al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur. J. Haematol.103(5), 500–509 (2019).
   PubMed Web of Science ®Google Scholar
• Reilly MC , ZbrozekAS, DukesEM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics4(5), 353–365 (1993).
   PubMed Web of Science ®Google Scholar
• Statacorp . Stata Statistical Software: release 17. (2021).
   Google Scholar
• Steinmetz TH , SinghM, LebiodaAet al. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. J Med Econ24(1), 114–122 (2021).
   PubMed Web of Science ®Google Scholar
• Gupta N , TaiM-H, KailaSet al. Real-world healthcare resource utilization and costs among patients with multiple myeloma in the United States. J. Clin. Oncol.40(Suppl. 16), e18811–e18811 (2022).
   Web of Science ®Google Scholar
• Gonzalez-McQuire S , YongK, LeleuHet al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ21(5), 450–467 (2018).
   PubMed Web of Science ®Google Scholar
• Martino M , RossiM, FerreriAet al. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Rev Hematol12(8), 665–684 (2019).
   PubMed Web of Science ®Google Scholar
• Engelhardt M , IhorstG, SinghMet al. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. Clinical Lymphoma Myeloma and Leukemia21(2), e160–e175 (2021).
   PubMed Web of Science ®Google Scholar
• Seitzler S , Finley-OliverE, SimonelliC, BazR. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol12(6), 419–424 (2019).
   PubMed Web of Science ®Google Scholar
• Kamal M , WangXS, ShiQet al. Symptom burden and its functional impact in patients with “symptomatic” relapsed or refractory multiple myeloma. Support. Care Cancer29(1), 467–475 (2021).
   PubMed Web of Science ®Google Scholar
• Zaleta AK , MillerMF, OlsonJSet al. Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma. Journal of the National Comprehensive Cancer Network18(8), 1087–1095 (2020).
   PubMed Web of Science ®Google Scholar
• Leblanc MR , HirscheyR, LeakBryant A, LeblancTW, SmithSK. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Qual. Life Res.29(6), 1419–1431 (2020).
   PubMed Web of Science ®Google Scholar
• Sparano F , CavoM, NiscolaP, CaravitaT, EfficaceF. Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. Support. Care Cancer26(7), 2075–2090 (2018).
   PubMed Web of Science ®Google Scholar
• Lonial S , LeeHC, BadrosAet al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol21(2), 207–221 (2020).
   PubMed Web of Science ®Google Scholar
• Lonial S , LeeHC, BadrosAet al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer127(22), 4198–4212 (2021).
   PubMed Web of Science ®Google Scholar
• Chari A , VoglDT, GavriatopoulouMet al. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. N. Engl. J. Med.381(8), 727–738 (2019).
   PubMed Web of Science ®Google Scholar
• Richardson PG , JagannathS, ChariAet al. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. eJHaem2(1), 48–55 (2021).
   PubMedGoogle Scholar
• Richardson PG , OriolA, LaroccaAet al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J. Clin. Oncol.39(7), 757–767 (2021).
   PubMed Web of Science ®Google Scholar
• Munshi NC , AndersonLD, ShahNet al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl. J. Med.384(8), 705–716 (2021).
   PubMed Web of Science ®Google Scholar
• Berdeja JG , MadduriD, UsmaniSZet al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet398(10297), 314–324 (2021).
   PubMed Web of Science ®Google Scholar
• Moreau P , GarfallAL, vande Donk NWCJet al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med.387(6), 495–505 (2022).
   PubMed Web of Science ®Google Scholar